

Figure S1. Immunohistochemical expression of m6A regulators within the prognostic model from the Human Protein Atlas. (A) Strong YTHDF2 staining of normal kidney tissue (<https://www.proteinatlas.org/ENSG00000198492-YTHDF2/tissue/kidney#img>). (B) Negative YTHDF2 staining of ccRCC tumor cells (<https://www.proteinatlas.org/ENSG00000198492-YTHDF2/pathology/renal+cancer#img>). (C) Low YTHDC2 staining of normal kidney tissue (<https://www.proteinatlas.org/ENSG00000047188-YTHDC2/tissue/kidney#img>). (D) Medium YTHDC2 staining of ccRCC tumor cells (<https://www.proteinatlas.org/ENSG00000047188-YTHDC2/pathology/renal+cancer#img>). (E) Strong FMR1 staining of normal kidney tissue (<https://www.proteinatlas.org/ENSG00000102081-FMR1/tissue/kidney#img>). (F) Negative FMR1 staining of ccRCC tumor cells (<https://www.proteinatlas.org/ENSG00000102081-FMR1/pathology/renal+cancer#img>). (G) Weak ELAVL1 staining of normal kidney tissue (<https://www.proteinatlas.org/ENSG00000066044-ELAVL1/tissue/kidney#img>). (H) Strong ELAVL1 staining of ccRCC tumor cells (<https://www.proteinatlas.org/ENSG00000066044-ELAVL1/pathology/renal+cancer#img>). (Patient id: TYHDF2_normal 2530; TYHEF2_cancer: 3039; YTHDC2_normal: 1933; YTHDC2_cancer: 1969; FMR1_normal: 2530; FMR1_cancer: 2477; ELAVL1_normal: 1933; ELAVL1_cancer: 3039).




Figure S2. Relationship between proteomic expression of FTO and BMI in our cohort. (A) The relationship between FTO level in paracancerous normal tissues and BMI. (B) The relationship between FTO level in cancer tissues and BMI (The FTO level was divided into low and high based on the median value). Analytic Method: Wilcoxon test. BMI, body mass index; FTO, fat mass and obesity-associated protein.

